Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity-Reference-Cited by-同舟云学术

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Published:2021-02-26 Issue:6532 Volume:371 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Larsen Mads Delbo¹²^ORCID,de Graaf Erik L.¹²^ORCID,Sonneveld Myrthe E.¹²,Plomp H. Rosina³^ORCID,Nouta Jan³,Hoepel Willianne⁴⁵^ORCID,Chen Hung-Jen⁶⁷^ORCID,Linty Federica¹²,Visser Remco¹²^ORCID,Brinkhaus Maximilian¹²,Šuštić Tonći¹²^ORCID,de Taeye Steven W.¹²^ORCID,Bentlage Arthur E. H.¹²^ORCID,Toivonen Suvi⁸^ORCID,Koeleman Carolien A. M.³,Sainio Susanna⁸,Kootstra Neeltje A.⁹,Brouwer Philip J. M.⁹^ORCID,Geyer Chiara Elisabeth⁴⁵^ORCID,Derksen Ninotska I. L.¹⁰²^ORCID,Wolbink Gertjan¹¹^ORCID,de Winther Menno⁶⁷^ORCID,Sanders Rogier W.⁹¹²^ORCID,van Gils Marit J.⁹^ORCID,de Bruin Sanne¹³,Vlaar Alexander P. J.¹³^ORCID,Rispens Theo¹⁰²^ORCID,den Dunnen Jeroen⁴⁵^ORCID,Zaaijer Hans L.¹⁴^ORCID,Wuhrer Manfred³^ORCID,Ellen van der Schoot C.¹²,Vidarsson Gestur¹²^ORCID,van Agtmael Michiel,Algera Anne Geke,van Baarle Frank,Bax Diane,van de Beek Diederik,Beudel Martijn,Bogaard Harm Jan,Bonta Peter I.,Bomers Marije,Bos Lieuwe,Botta Michela,de Bree Godelieve,Brouwer Matthijs C.,Brabander Justin,de Bruin Sanne,Bugiani Marianna,Bulle Esther,Chouchane Osoul,Cloherty Alex,Elbers Paul,Fleuren Lucas,Geerlings Suzanne,Geerts Bart,Geijtenbeek Theo,Girbes Armand,Goorhuis Bram,Grobusch Martin P.,Hafkamp Florianne,Hagens Laura,Hamann Jorg,Harris Vanessa,Hemke Robert,Hermans Sabine M.,Heunks Leo,Hollmann Markus W.,Horn Janneke,Hovius Joppe W.,de Jong Menno,Koning Rutger,van Mourik Niels,Nellen Jeaninne,Nossent Esther J.,Paulus Frederique,Peters Edgar,van der Poll Tom,Preckel Bennedikt,Prins Jan M.,Raasveld Jorinde,Rijnders Tom,Schinkel Michiel,Schultz Marcus,Schuurmans Alex R.,Sigaloff Kim,Smit Marry,Stijnis Cornelis S.,Stilma Willemke,Teunissen Charlotte,Thoral Patrick,Tsonas Anissa,van der Valk Marc,Veelo Denise,Vlaar Alexander P. J.,de Vries Heder,van Vugt Michèle,Wiersinga W. Joost,Wouters Dorien,Zwinderman A. H. (Koos), ,

Affiliation:

1. Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands.

2. Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

3. Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.

4. Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands.

5. Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

6. Department of Medical Biochemistry, Experimental Vascular Biology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

7. Department of Cardiovascular Sciences, Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, Netherlands.

8. Finnish Red Cross Blood Service, Helsinki, Finland.

9. Department of Medical Microbiology, Amsterdam UMC, Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, Netherlands.

10. Department of Immunopathology, Sanquin Research, Amsterdam, Netherlands.

11. Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Netherlands.

12. Weill Medical College, Cornell University, New York, USA.

13. Department of Intensive Care Medicine, Amsterdam UMC (Location AMC), University of Amsterdam, Amsterdam, Netherlands.

14. Department of Blood-borne Infections, Sanquin, Amsterdam, Netherlands.

Abstract

A single sugar makes all the difference Antibodies are divided into several classes based on their nonvariable tail (Fc) domains. These regions interact with disparate immune cell receptors and complement proteins to help instruct distinct immune responses. The Fc domain of immunoglobulin G (IgG) antibodies contains a conserved N-linked glycan at position 297. However, the particular glycan used at this position is highly variable. IgG lacking core fucosylation at this position initiates enhanced antibody-dependent cellular cytotoxicity by increased affinity to the Fc receptor FcRIIIa. Larsen et al. report that COVID-19 patients with severe symptoms have increased levels of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG afucosylation compared with patients with mild disease. These findings suggest that treatment of COVID-19 patients with fucosylated anti–SARS-CoV-2 antibodies may circumvent pathologies associated with severe COVID-19. Science , this issue p. eabc8378

Funder

Landsteiner Foundation for Blood Transfusion Research

H2020 European Research Council

Seventh Framework Programme

ZonMW

Amsterdam Infection and Immunity Institute

Netherlands Organization for Scientific Research

Marie Skłodowska-Curie

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary